New drug targets genetic weakness in deadly brain tumor

NCT ID NCT06105619

Ongoing Disease control Sponsor: Beijing Pearl Biotechnology Limited Liability Company Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This clinical trial tests a new drug called vebreltinib (PLB1001) in people with a recurrent form of glioblastoma that has a specific genetic change (ZM fusion gene). The study compares vebreltinib to standard chemotherapy to see if it helps people live longer. About 84 participants will be enrolled across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vebreltinib (PLB1001)
What this could lead to: If successful, this could provide a new targeted treatment option for people with a specific genetic subtype of recurrent glioblastoma, potentially improving survival.
What could go wrong: This is an early-to-mid-stage trial with only 84 participants. The drug may not prove more effective than standard chemotherapy, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 4 glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Beijing Tiantan Hospital,Capital Medical University

Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.